Plasma Levels of Pentosidine, Carboxymethyl-Lysine, Soluble Receptor for Advanced Glycation End Products, and Metabolic Syndrome: The Metformin Effect

Table 3

Treatment effect of metformin on pentosidine and CML levels in patients with MetS.

	Treated patients	Untreated patients
Pentosidine (pmol/mL)	140.72 (62.07–249.51)	372.45 (132.55–556.68)	0.01
CML (pg/mL)	504.39 (405.52–784.7)	439.76 (273.12–460.98)	0.083

Values are median (25%–75%) percentiles; CML: N (carboxymethyl) lysine.